Home > Insider Trading > Filing (0001209191-15-080927)

Filing Details

Accession Number:: 0001209191-15-080927
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-11-18 16:19:37
Reporting Period:: 2015-11-16

Filing Date:: 2015-11-18
Accepted Time:: 2015-11-18 16:19:37
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1439222	Agios Pharmaceuticals Inc	AGIO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1581954	Duncan John Higgons	C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-11-16	10,909	$0.47	92,744	No	4	M	Direct
Common Stock	Acquisiton	2015-11-16	2,479	$0.47	95,223	No	4	M	Direct
Common Stock	Acquisiton	2015-11-16	6,612	$2.34	101,835	No	4	M	Direct
Common Stock	Disposition	2015-11-16	20,000	$61.51	81,835	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2015-11-16	10,909	$0.00	10,909	$0.47
Common Stock	Stock option (right to buy)	Disposition	2015-11-16	2,479	$0.00	2,479	$0.47
Common Stock	Stock option (right to buy)	Disposition	2015-11-16	6,612	$0.00	6,612	$2.34

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
214,113	2021-03-01	No	4	M	Direct
211,634	2021-03-01	No	4	M	Direct
205,022	2022-04-05	No	4	M	Direct

Footnotes

This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.32 to $62.77. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price
This option was granted on March 2, 2011. The shares underlying this option vest as to 25% of the shares on January 31, 2012, with the remaining 75% vesting in 36 equal monthly installments thereafter.
This option was granted on March 2, 2011 for the purchase of 3,636 shares of common stock. The option vests as to 33% of the underlying shares upon the achievement of a performance milestone and with the remaining 67% vesting in 24 equal monthly installments thereafter. The performance criteria for the performance milestone were met on July 19, 2013.
This option was granted on April 6, 2012 for the purchase of 63,636 shares of common stock. The option vests as to 25% of the underlying shares upon the achievement of a performance milestone, as to an additional 50% upon the achievement of a second performance milestone, and as to the remaining 25% on the first anniversary of the first date that both performance milestones were achieved. The performance criteria for the first performance milestone were met on March 18, 2013, resulting in the vesting of the option as to 15,909 shares. The performance criteria for the second performance milestone were met on April 4, 2014, resulting in the vesting of the option as to 31,818 shares. The remaining 15,908 shares vested on April 4, 2015.